Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm burosumab study in adults with X-linked hypophosphatemia
2015-001775-41Phase 3Completed
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of burosumab in X-linked hypophosphataemia (XLH), sponsored by Ultragenyx Pharmaceutical Inc. Primary endpoint: Percent change from baseline in excess osteoid at Week 48. Started Oct 2015; status: completed.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphataemia (XLH)
Beyond the preview
Go deeper on 2015-001775-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001775-41.